Hepatitis - Viral

This is a PDF version of the following document:
Disease Type 1: Pathogen-Based Diseases
Disease 16: Hepatitis – Viral

You can always find the most up to date version of this document at https://www.std.uw.edu/go/pathogen-based/viral-hepatitis/core-concept/all.

References


- Bridges CB, Coyne-Beasley T. Advisory committee on immunization practices recommended


- CDC. Update to: CDC viral hepatitis surveillance, United States 2016. [CDC] -


- Lu PJ, Byrd KK, Murphy TV. Hepatitis A vaccination coverage among adults 18-49 years traveling to a country of high or intermediate endemicity, United States. Vaccine. 2013;31:2348-57. [PubMed Abstract] -


Racznia GA, Bulkow LR, Bruce MG, et al. Long-term immunogenicity of hepatitis A virus...
[PubMed Abstract]

[PubMed Abstract]

[PubMed Abstract]

[PubMed Abstract]

[PubMed Abstract]

[PubMed Abstract]

[PubMed Abstract]

• Scott JD, Gretch DR. Molecular diagnostics of hepatitis C virus infection: a systematic review. JAMA. 2007;297:724-32.
[PubMed Abstract]

[PubMed Abstract]

[PubMed Abstract]

[PubMed Abstract]

[PubMed Abstract]
• Trépo C, Chan HL, Lok A. Hepatitis B virus infection. Lancet. 2014;384:2053-63.  
  [PubMed Abstract]

  [PubMed Abstract]

  [PubMed Abstract]

  [PubMed Abstract]

  [PubMed Abstract]

  [PubMed Abstract]

  [2015 STD Treatment Guidelines]

  [2015 STD Treatment Guidelines]

  [PubMed Abstract]
Figures

Figure 1 Test Figure

Test Publish Caption update 8

Test

<table>
<thead>
<tr>
<th>Content Analytics</th>
</tr>
</thead>
<tbody>
<tr>
<td>Words in Modules</td>
</tr>
<tr>
<td>97,033</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Lesson Word Counts</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.1 Diagnosis and Management of Acne: 5,816 words</td>
</tr>
<tr>
<td>HBsAg</td>
</tr>
<tr>
<td>-------</td>
</tr>
<tr>
<td>(+)</td>
</tr>
<tr>
<td>(+)</td>
</tr>
<tr>
<td>(-)</td>
</tr>
<tr>
<td>(-)</td>
</tr>
<tr>
<td>(-)</td>
</tr>
<tr>
<td>(-)</td>
</tr>
</tbody>
</table>

Abbreviations: HBV = hepatitis B Virus; HbsAg = hepatitis B surface antigen; anti-HBs = hepatitis B surface antibody; anti-HBc = hepatitis B core antibody
Table 5.

**Recommendations for Postexposure Prophylaxis Following Exposure to Hepatitis A Virus (HAV)**

<table>
<thead>
<tr>
<th>Indication/Age Group</th>
<th>Risk Category/Health Status</th>
<th>HAV Vaccine</th>
<th>Immune Globulin</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;1 year</td>
<td>Healthy</td>
<td>No</td>
<td>0.1 mL/kg*</td>
</tr>
<tr>
<td>1-40 years</td>
<td>Healthy</td>
<td>1 dose^</td>
<td>None</td>
</tr>
<tr>
<td>&gt;40 years</td>
<td>Healthy</td>
<td>1 dose^</td>
<td>0.1 mL/kg§</td>
</tr>
<tr>
<td>≥1 Year</td>
<td>Immunocompromised or chronic liver Disease</td>
<td>1 dose^</td>
<td>0.1 mL/kg#</td>
</tr>
<tr>
<td>≥1 Year</td>
<td>Vaccine</td>
<td>No</td>
<td>0.1 mL/</td>
</tr>
</tbody>
</table>

**Abbreviations**

* Measles, mumps, and rubella vaccine should not be administered for at least 3 months after receipt of Immune globulin.

^ A second dose is not required for postexposure prophylaxis; however, for long-term immunity, the hepatitis A vaccination series should be completed with a second dose at least 6 months after the first dose.

§ The provider’s risk assessment should determine the need for immune globulin administration. If the provider’s risk assessment determines that both vaccine and immune globulin are warranted, HepA vaccine and immune globulin should be administered simultaneously at different anatomic sites.

# Vaccine and immune globulin should be administered simultaneously at different anatomic sites.

**Life-threatening allergic reaction to a previous dose of hepatitis A vaccine, or allergy to any vaccine component.**

Source:
